A proposed Bayer combination Aspirin settlement has been reached in the Bayer Combination Aspirin Multidistrict Litigation, of which firm partner, Michael London, serves as Co-Lead and Liaison Counsel. The $15 million settlement, which has been preliminarily approved by the Court, would provide funds for consumers who purchased Bayer Aspirin with Heart Advantage between Jan. 1, 2008 and July 23, 2012, and consumers who purchased Bayer Women’s Low-Dose Aspirin + Calcium between Jan. 1, 2000 and July 23, 2012.
A notice with the rights and responsibilities of class members is available here. If you are a member of the class, you may fill out this claim form to make a claim for payment from the settlement fund.
The settlement is not yet final and must be approved by the court before settlement funds can be distributed to class members. More information about this settlement is available at http://www.bayercombinationaspirinsettlement.com/
As way of brief background, in November 2008 Douglas & London P.C. filed a class action complaint against Bayer Healthcare arising out of its alleged unlawful marketing of two combination aspirin products: Bayer Aspirin with Heart Advantage and Bayer Women’s Low Dose Aspirin + Calcium. Specifically, it was alleged that the two products were sold by Bayer Healthcare without approval by the Food and Drug Administration and without proof that the two products were safe and effective as advertised. In April 2009, this action and others were consolidated in the United States District Court for the Eastern District of New York before the Honorable Judge Brian M. Cogan. Thereafter, a Master Complaint was filed on behalf of all plaintiffs. Following two years of extensive discovery and motion practice, the proposed settlement was reached.